HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies.

doi:10.1007/s10549-010-0886-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies.

Breast cancer research and treatment - 1 Dec 2010

Lu Su, Wang Zhanwei, Liu Hong, Hao Xishan

Abstract excerpt

Proto-oncogene HER2 (also known as erbB-2 or neu) plays an important role in the carcinogenesis and the prognosis of breast cancer. Many epidemiological studies have been conducted to explore the association between the HER2 Ile655Val polymorphism and breast cancer risk. However, inconsistency existed in the results. Therefore, we performed a meta-analysis of 27 published case-control studies including 11,504...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Black People
Share to Breast Neoplasms
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Odds Ratio

Share to Proto-Oncogene Mas

Share to Receptor, ErbB-2

Share to Risk Assessment

Source

Open in PubMed

Identifiers

PMID: 20401632
DOI: 10.1007/s10549-010-0886-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.